Lipocine financials
$2.16+3.35%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $1.1M | $114.6K | $500.0K | $0.00 | $3.5M | $0.00 | $89.6K | $7.6M | $216.2K | -$3.1M |
| Gross profit | $0.00 | $0.00 | $1.1M | $114.6K | $500.0K | $0.00 | $3.5M | $0.00 | $89.6K | $7.6M | $216.2K | -$3.1M |
| Gross margin | — | — | 100.0% | 100.0% | 100.0% | — | 100.0% | — | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$3.0M | -$4.0M | -$2.5M | -$3.4M | -$2.5M | -$2.2M | $1.5M | -$2.6M | -$3.3M | $3.2M | -$2.6M | -$7.0M |
| Net income | -$2.6M | -$3.7M | -$2.4M | -$3.2M | -$2.2M | -$1.9M | $1.8M | -$2.2M | -$3.1M | $3.5M | -$2.3M | -$6.7M |
| Net margin | — | — | −206.9% | −2781.5% | −441.1% | — | 51.0% | — | −3426.2% | 46.1% | −1055.7% | 213.0% |
| Diluted EPS | $-0.32 | $-0.54 | $-0.35 | $-0.59 | $-0.41 | $-0.35 | $0.32 | $-0.41 | $-0.56 | $0.66 | $-0.43 | $-1.27 |
| EBITDA | -$3.0M | -$4.0M | -$2.5M | -$3.3M | -$2.5M | -$2.2M | $1.6M | -$2.6M | -$3.3M | $3.2M | -$2.6M | -$7.0M |
| Operating cash flow | -$3.0M | -$2.3M | -$2.9M | -$3.0M | -$1.9M | -$2.0M | $1.7M | -$2.8M | -$2.5M | $2.4M | -$2.0M | -$2.6M |
| Free cash flow | -$3.0M | -$2.3M | -$2.9M | -$3.0M | -$1.9M | -$2.0M | $1.7M | -$2.9M | -$2.5M | $2.4M | -$2.0M | -$2.6M |
| Diluted shares | 8.2M | 6.8M | 6.7M | 5.4M | 5.4M | 5.3M | 5.6M | 5.3M | 5.3M | 5.4M | 5.3M | 5.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.0M | $5.0M | $5.2M | $3.9M | $6.0M | $3.4M |
| Short-term investments | $18.3M | $19.7M | $9.7M | $11.2M | $11.9M | $16.4M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $23.8M | $25.4M | $17.0M | $16.1M | $18.6M | $20.5M |
| Total liabilities | $2.1M | $2.5M | $2.5M | $1.9M | $1.4M | $1.3M |
| Shareholders' equity | $21.8M | $22.8M | $14.5M | $14.1M | $17.1M | $19.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology